Sanofi Income Taxes 2012-2026 | SNY
Sanofi annual/quarterly income taxes history and growth rate from 2012 to 2026. Income taxes can be defined as the total amount of income tax expense for the given period.
- Sanofi income taxes for the quarter ending March 31, 2026 were $0.492B, a 2.99% decline year-over-year.
- Sanofi income taxes for the twelve months ending March 31, 2026 were $1.165B, a 28.6% decline year-over-year.
- Sanofi annual income taxes for 2025 were $1.18B, a 9.43% decline from 2024.
- Sanofi annual income taxes for 2024 were $1.303B, a 24.86% decline from 2023.
- Sanofi annual income taxes for 2023 were $1.734B, a 17.96% decline from 2022.
|
Sanofi Annual Income Taxes (Millions of US $) |
|
|---|---|
| 2025 | $1,180 |
| 2024 | $1,303 |
| 2023 | $1,734 |
| 2022 | $2,114 |
| 2021 | $1,843 |
| 2020 | $2,071 |
| 2019 | $156 |
| 2018 | $568 |
| 2017 | $1,946 |
| 2016 | $1,467 |
| 2015 | $787 |
| 2014 | $1,557 |
| 2013 | $1,013 |
| 2012 | $1,458 |
| 2011 | $634 |
|
Sanofi Quarterly Income Taxes (Millions of US $) |
|
|---|---|
| 2026-03-31 | $492 |
| 2025-12-31 | $-383 |
| 2025-09-30 | $795 |
| 2025-06-30 | $261 |
| 2025-03-31 | $507 |
| 2024-12-31 | $-8 |
| 2024-09-30 | $810 |
| 2024-06-30 | $322 |
| 2024-03-31 | $178 |
| 2023-12-31 | $333 |
| 2023-09-30 | $613 |
| 2023-06-30 | $295 |
| 2023-03-31 | $493 |
| 2022-12-31 | $962 |
| 2022-09-30 | $605 |
| 2022-06-30 | $173 |
| 2022-03-31 | $373 |
| 2021-09-30 | $718 |
| 2021-06-30 | |
| 2021-03-31 | $487 |
| 2020-09-30 | $573 |
| 2020-03-31 | $479 |
| 2019-09-30 | $298 |
| 2019-03-31 | $290 |
| 2018-03-31 | $230 |
| 2017-12-31 | $803 |
| 2017-09-30 | $484 |
| 2017-06-30 | $301 |
| 2017-03-31 | $358 |
| 2016-12-31 | $396 |
| 2016-09-30 | $513 |
| 2016-06-30 | $429 |
| 2016-03-31 | $129 |
| 2015-09-30 | $303 |
| 2015-06-30 | $574 |
| 2014-06-30 | $480 |
| 2013-06-30 | $59 |
| 2012-06-30 | $479 |
| 2012-03-31 | $650 |
| 2011-12-31 | $-590 |
| 2011-09-30 | $564 |
| 2011-06-30 | $292 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |